Pregnancy test: Nora's $18M series B will fund miscarriage phase II bid
By Randy Osborne
Friday, April 18, 2014
In stealth mode until about six months ago, Nora Therapeutics Inc. raised $18 million in series B cash to expand the development of NT100 into a second phase II trial in women with unexplained recurrent loss of pregnancy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.